Serology testing in the COVID-19 pandemic response
Serology testing in the COVID-19 pandemic response
复制标题
DOI：
10.1016/s1473-3099(20)30517-x
复制
发表时间：
2020-09-01
影响因子：
56.3
通讯作者：
Heymann, David L.
中科院分区：
文献类型：
--
作者：
Peeling, Rosanna W.;Wedderburn, Catherine J.;Heymann, David L.
全球合作的崩溃和国际团结的失败导致许多低收入和中等收入国家在COVID-19大流行应对中无法获得分子诊断。然而，由于缺乏对感染的免疫反应动力学的知识，导致在推荐使用快速免疫诊断测试时犹豫不决，尽管快速血清学测试已商品化并可扩展。根据我们对病毒传染性和宿主反应的知识和理解，我们敦促没有能力进行大规模分子检测的国家研究在社区环境中使用血清学检测对有症状患者进行分诊，检测确诊病例的接触者，以及进行情况分析和监测。世卫组织研发蓝图专家组确定了8项研发重点，其中最重要的一项是动员关于在社区一级使用的快速即时诊断的研究。这项研究应使控制规划了解快速血清学检测所需的性能和效用，如果将其专门应用于随后将采取的适当公共卫生措施，可以产生巨大的影响。
The collapse of global cooperation and a failure of international solidarity have led to many low-income and middle-income countries being denied access to molecular diagnostics in the COVID-19 pandemic response. Yet the scarcity of knowledge on the dynamics of the immune response to infection has led to hesitation on recommending the use of rapid immunodiagnostic tests, even though rapid serology tests are commercially available and scalable. On the basis of our knowledge and understanding of viral infectivity and host response, we urge countries without the capacity to do molecular testing at scale to research the use of serology tests to triage symptomatic patients in community settings, to test contacts of confirmed cases, and in situational analysis and surveillance. The WHO R&D Blue Print expert group identified eight priorities for research and development, of which the highest is to mobilise research on rapid point-of-care diagnostics for use at the community level. This research should inform control programmes of the required performance and utility of rapid serology tests, which, when applied specifically for appropriate public health measures to then be put in place, can make a huge difference.